Nội dung

Available online http://arthritis-research.com/content/6/1/19 Review A paragon of self-tolerance: CD25+CD4+ regulatory T cells and the control of immune responses Zoltán Fehérvári and Shimon Sakaguchi Department of Experimental Pathology, Kyoto University, Kyoto, Japan Correspondence: Shimon Sakaguchi (e-mail: shimon@frontier.kyoto-u.ac.jp) Received: 23 Sep 2003 Accepted: 3 Dec 2003 Published: 19 Dec 2003 Arthritis Res Ther 2004, 6:19-25 (DOI 10.1186/ar1037) © 2004 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362) Abstract The interest in naturally arising regulatory T (TR) cells as a paradigm for maintaining immunological selftolerance has undergone an explosive re-emergence in recent years. This renaissance was triggered by several key experimental observations and the identification of specific molecular markers that have enabled the isolation and experimental manipulation of these cells. Although their existence was once controversial, a large body of evidence now highlights the critical roles of TR cells in maintaining immunological self-tolerance. Furthermore, abnormality of natural TR cells can be a primary cause of autoimmune and other inflammatory diseases in humans. Keywords: CD25+CD4+, Foxp3, regulatory cells, self-tolerance, suppression Introduction The random nature of T-cell receptor (TCR) generation inevitably leads to the appearance of deleterious autoreactive clones, but the vast majority of such cells are purged in the thymus during negative selection. However, there is abundant evidence showing that significant numbers of autoreactive cells can ‘slip through the net’ of central tolerance into the periphery and thereby potentially mediate autoimmunity. This phenomenon can be readily demonstrated by the experimental induction of autoimmunity when otherwise normal animals are injected with self proteins plus a strong adjuvant [1]. The fact that healthy animals harbour such destructive cells implies the existence of mechanisms operating in the periphery that are able to effectively prevent their activation. Experimental evidence has indeed revealed numerous avenues by which this can occur, among them immune ignorance, peripheral deletion/anergy, and dominant suppression (reviewed in [2]). The existence of a specific T cell subset that could dominantly suppress immune responses was first proposed by Gershon and Kondo in 1970 [3]. The concept devel- oped from experiments suggesting that tolerance was an active cell-mediated process and could be transferred into naïve animals. Elaborate circuits involving suppressor, contrasuppressor and veto cells were proposed to explain the maintenance of self-tolerance; however, the inability to clone any actual suppressor cells or identify critical molecules associated with them led to the decline of such a model. Furthermore, the subsequent emergence of the Th1–Th2 paradigm seemed largely able to subsume suppression phenomena by the patterns of regulatory cytokines that these cells could secrete, and the parsimony thus offered seemed much more attractive as a theory. In contrast, accumulated evidence from the mid-1980s has shown that depletion of a particular T cell subset from normal animals can cause autoimmune disease similar to the counterparts in humans, and that reconstitution of this subset can prevent these diseases. Subsequent detailed phenotypic characterisation of such autoimmune preventative cells now leaves no doubt of the existence of TR cells as crucial mediators of self-tolerance in both animal models and humans. APC = antigen-presenting cell; DC = dendritic cell; GITR = glucocorticoid-induced tumour necrosis factor family related protein; IBD = inflammatory bowel disease; IL = interleukin; IL-2R, interleukin-2 receptor; TCR = T-cell receptor; TGF = transforming growth factor; Th = T helper cell; TR cell = regulatory T cell. 19 Arthritis Research & Therapy Vol 6 No 1 Fehérvári and Sakaguchi Defining a ‘regulatory cell’ Broadly speaking, T cells with regulatory properties can be divided into two types: naturally occurring thymically generated regulatory cells, defined here as ‘TR cells’, and those generated by antigenic stimulation under special conditions in the periphery, referred to variously as ‘Th3’, ‘Tr1’ cells or ‘adaptive regulatory cells’ (see, for example, [4]). This review will focus chiefly on the naturally arising suppressive TR cells. A discrete molecular description of TR cells has proved to be a key issue in this field and was indeed one of the major stumbling blocks to their original exposition. Early clues hinting at the identity of regulatory cells emerged from experimental models of autoimmune disease. Many such models require the induction of lymphopoenia in genetically susceptible strains of rodents, for example 3-day-old neonatal thymectomy or adult thymectomy coupled with an immunosuppressive treatment such as cyclophosphamide [5–7]. Depending on the strain background, experimental manipulations of this kind result in a variety of autoimmune diseases such as thyroiditis, gastritis, oophoritis and orchitis. It was subsequently shown that induction of such autoimmunity could be prevented by the transfer of normal CD4+ splenocytes or CD4+CD8– thymocytes [7–10]. Collectively, such data strongly suggested that a cell population with a crucial role in maintaining self-tolerance was resident within the normal T lymphocyte pool. Attempts were then made to phenotype putative TR cells more specifically by isolating the T lymphocyte fraction that harboured regulatory activity. Sakaguchi and colleagues managed to first identify the CD5 molecule as a marker for TR cells by demonstrating that otherwise normal lymphocytes depleted of CD5highCD4+ cells induced broad-spectrum autoimmunity when transferred into athymic nude mice [11]. Unfractionated CD4+ cells (which contain CD5high-expressing cells) prevented the induction of autoimmunity when transferred together with the CD5low cells, implying that the TR cells were contained specifically within the CD5high compartment. Subsequent experiments aimed at homing in yet further on TR cell-specific markers have identified a number of other potential candidate molecules. For instance, CD45RB seems to divide T cells into two distinct functional subsets [12]. Lymphopoenic mice transferred with CD45RBhigh cells develop a lethal wasting disease characterised by severe inflammatory bowel disease (IBD), whereas unfractionated T cells or CD45RBlow cells alone cause no disease. Importantly, co-transfer of the CD45RBlow and CD45RBhigh populations results in protection of the mice from colitis. 20 More recently, the most useful surface marker for TR cells has proved to be the interleukin-2 (IL-2) receptor α-chain, CD25 [13]. About 5–10% of CD4+ T cells and less than 1% of CD8+ peripheral T cells constitutively express CD25 in normal naïve mice, and such cells are found in the CD5high and CD45RBlow T cell fractions. Indeed, transfer of CD25-depleted CD4+ T cells to athymic mice results in a variety of autoimmune diseases, whereas transfer with CD25+CD4+ cells inhibits such disease development. Moreover, CD25+CD4+ cells in normal naïve mice exhibit clear immunosuppressive properties in vitro and in vivo [13,14]. It now seems that the naturally occurring CD25+CD4+ population could account for the regulatory effect of CD5high and CD45RBlow CD4+ T cells. A comprehensive characterisation of the surface profile of TR cells has revealed them to be quite distinct from conventional naïve effector T cells. Aside from the constitutive expression of CD25, TR cells show elevated levels of adhesion molecules such as CD11a (LFA-1), CD44, CD54 (ICAM-1), CD103 (αEβ7 integrin) in the absence of any apparent exogenous antigenic stimulation [14,15]. Naturally occurring CD25+CD4+ cells additionally express CD152 (CTLA-4), a molecule classically only expressed after T cell activation [16–18]. There is some evidence to suggest that TR cells might also exhibit a characteristic chemokine receptor profile, with mouse CD25+CD4+ cells expressing elevated levels of CCR5 and their human counterparts expressing CCR4 and CCR8 [19,20]. Such a distinctive pattern of chemokine receptors suggests that TR cells might be rapidly recruited to sites of inflammation and thereby efficiently control immune responses. Most recently, several groups have demonstrated that glucocorticoid-induced tumour necrosis factor family related protein (GITR) is predominantly expressed at both the RNA and protein levels by CD25+CD4+ cells [15,21,22]. Administration of the anti-GITR monoclonal antibody, DTA-1, in vivo elicits autoimmune disease, suggesting that this molecule has an important functional role in maintaining TR cell suppression [22]. The surface marker profile of TR cells is thus quite different from that of naïve T cells. However, it should be noted that most, if not all, of their apparently characteristic molecules are upregulated during conventional T cell activation. This similarity to otherwise normal but primed T cells is potentially problematic when trying to identify or isolate true TR cells and precludes the use of CD25 alone (or any other surface molecule yet found) as an infallible marker. This caveat aside, several important distinctions still remain between the surface phenotype of TR and primed T cells, but they are more relative than absolute. For example, although both primed T cells and TR cells express CD25, the latter does so to a higher level and more stably. Indeed, when stimulation of normal T cells ceases, CD25 expression is lost, whereas TR cells revert to their original constitutive expression level [23]. In addition, CD25+ cells generated from originally CD25–CD4+ cells show no suppressive ability either in vitro or in vivo [23]. As a component of the high-affinity IL-2 receptor, CD25 itself is Available online http://arthritis-research.com/content/6/1/19 essential for the survival of TR cells, and the cells are exquisitely sensitive to an absence of signalling through this receptor [24]. Clear evidence for this can be seen by the almost total absence of CD25+CD4+ cells in IL-2-deficient mice. In conclusion, the similarities between TR cells and primed T cells are therefore probably only a reflection of a shared activation state. As noted above, the search for a definitive TR cell marker has been fraught with complications and an occasional lack of certitude regarding their undeniable existence as a functionally distinct population rather than simply another activation state of conventional T cells. However, some very recent data have gone some way to demonstrating conclusively that TR cells are a genuine T cell lineage, in the process identifying a seemingly unambiguous marker [25–27]. Studies with the Scurfy (sf) mutant mouse model provided the required breakthrough. The Scurfy mouse exhibits a fatal X-linked lymphoproliferative disease that is mediated by highly activated CD4+ T cells and is akin to the phenotype of both CTLA-4 and transforming growth factor (TGF)-β knockout mice [28–32]. Subsequent work mapped the sf mutation to a novel forkhead/winged-helix family transcriptional repressor termed Foxp3, which encodes the protein scurfin [33]. A mutation in the human orthologue, FOXP3, has also been identified as the underlying cause of the aggressive autoimmune syndrome IPEX (for Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome) [33–35]. The overt immunological similarities seen with genetic defects of Foxp3 and the experimental depletion of CD25+CD4+ TR cells led several groups to investigate the potential role of Foxp3 in the development and function of TR cells. Three independent groups were able to demonstrate that Foxp3 mRNA [25–27] and the encoded protein [27] were specifically expressed only in naturally arising CD25+CD4+ TR cells and, critically, were never observed in normal T cells even after they had been activated and acquired the expression of CD25/GITR. However, a very low level of Foxp3 expression was observed in CD25–CD4+ T cells; this appeared to be attributable to a small population of CD25–CD45RBlowGITRhigh TR cells ([26], M Ono, manuscript in preparation). In addition, TR cells were unable to develop in the absence of Foxp3, as demonstrated by the use of sf mice or by the targeted deletion of Foxp3 [25,27]. Finally, and most convincingly, retroviral transduction of Foxp3 into conventional CD25– Foxp3– T cells converted them into phenotypical and functional TR cells capable of effectively suppressing both in vitro and in vivo [26,27]. Thus Foxp3 seems to be a ‘master gene’ controlling the normal development and/or function of naturally occurring TR cells. As yet there are very few data detailing the role and expression patterns of FOXP3 in human cells. Some of the early indications, both published and unpublished, have shown FOXP3 expression in human CD25+CD4+ T cells ([36], H Yagi and S Sakaguchi, unpublished results); however, it already seems that there are some discrepancies with the murine data. For example, there seem to be considerable differences in FOXP3 expression between individuals and, more significantly, FOXP3 might be inducible in human CD25–CD4+ cells (which start off apparently FOXP3–) after anti-CD3/anti-CD28 stimulation [36]. It remains to be determined whether this simply represents an expansion to detectability of the tiny Foxp3+GITR+CD25–CD4+ population described above ([26], M Ono, manuscript in preparation) or is a genuine property of human T cells radically different from that of mice. The suppressive properties of TR cells can be modelled in vitro by mixing titrated numbers of highly purified CD25+CD4+ cells and CD25–CD4+ (or CD25–CD8+) responder cells plus a TCR stimulus such as anti-CD3, ConA or antigen-presenting cells (APCs) plus antigenic peptide. Under such conditions, the CD25+ population suppresses both the proliferation and IL-2 production of the CD25– cells in a dose-dependent manner [37,38]. The TR cells require TCR stimulation to exert any suppressive effects, but once this condition has been satisfied the ensuing suppression is non-specific for antigen [37,38]. Suppression is therefore an active process and can be directed against bystander cells. Curiously, the CD25+CD4+ TR cells themselves are anergic in vitro; that is, they do not proliferate or produce IL-2 in response to conventional T cell stimuli. However, this anergy can be broken by a sufficiently potent stimulus such as the addition of exogenous IL-2 or anti-CD28, or the use of mature dendritic cells as APCs [37,39]. Interestingly, anergy seems to be the default state for TR cells, because they revert to it once IL-2 is withdrawn [37,38]. However, the anergy in vitro is not reflected in vivo, wherein TR cells seem to have a highly active rate of turnover [24]. An anergic state also seems to be closely related to TR cells’ suppressive ability because if it is broken there is a concomitant loss of regulatory activity both in vitro and in vivo [37]. Table 1 summarises what is currently known about the TR cell phenotype. Development and origin CD25+CD4+ TR cells are produced by the normal thymus as fully functioning suppressive cells, and such thymocytes exhibit apparently all the properties of their matured peripheral counterparts [14]. Itoh and colleagues showed that the adoptive transfer of CD25-depleted thymocytes to syngeneic nude mice recipients led to a similar spectrum of autoimmune disease to that with CD25–CD4+ peripheral cells [14]. CD25+CD4+ thymocytes are also anergic and suppressive in vitro and exhibit a classic TR cell surface phenotype, for example elevated levels of activa- 21 Arthritis Research & Therapy Vol 6 No 1 Fehérvári and Sakaguchi Table 1 Comparison of the phenotype of conventional naïve CD4+ T cells and CD4+ regulatory cells (TR) Conventional naïve helper T cell Natural regulatory T cell (TR) Foxp3– Foxp3+ CD5low, CD11alow, CD25low, CD38low, CD44low, CD45RBhigh, CD54low, CD103εlow, GITRlow CD5high, CD11ahigh, CD25high, CD38high, CD44high, CD45RBlow, CD54high, CD103high, GITRhigh About 90–95% of splenic CD4+ T cells About 5–10% of splenic CD4+ T cells Responsive to conventional T cell stimuli Anergic to conventional T cell stimuli Non-suppressive Suppressive Many of the distinctions are not absolute; for instance, activated non-regulatory effector T cells express cell surface markers with a pattern similar to that of TR cells, so such discrimination is possible only with constitutive expression. Currently, expression of Foxp3 seems to be the most accurate marker for TR cells because this does not vary with the activation state. tion markers such as CTLA-4 and GITR; importantly they are also Foxp3+ [14,22,26]. TR cells can develop in TCR transgenic mice specific for an exogenous peptide; however, those cells that do develop show a strong bias for expressing an endogenous TCR-α chain paired with the transgenic β-chain, in contrast to CD25–CD4+ cells, which predominantly expressed only the whole transgenic TCR [14,40]. When these mice were bred onto a RAG-2–/– or TCRα–/– background (both of which lack endogenous α-chain gene rearrangements), CD25+CD4+ cells were eliminated, suggesting that signalling through TCRs expressing the endogenous TCRα-chains was necessary for their development [14,40]. Furthermore, studies with a doubly transgenic mouse have also demonstrated that the CD25+CD4+ TR cells show a high self-reactivity and differentiate on thymic epithelial cells [41,42]. Thus, the central generation of CD25+CD4+ TR cells is dependent on relatively high-avidity TCR interactions with self-peptide/MHC complexes within the thymic stroma. However, it is still not clear why the relatively self-reactive TR cell precursors escape thymic negative selection and instead begin a developmental programme involving Foxp3. Although apparently not required for the activation of suppressive functions, the classic co-stimulatory molecule CD28 seems to be important in the thymic production of TR cells and/or their peripheral maintenance, as demonstrated by markedly reduced TR cell numbers in CD28–/– animals [18]. A similar decrease in the TR cell population could also be observed by blockading CD28–B7 interactions with CTLA-4-immunoglobulin fusion protein [18]. Finally, CD40–CD40L interactions also seem to be important in the development of TR cells, as shown by their marked decrease in CD40–/– mice [43]. 22 The extra-thymic generation of TR cells from conventional CD25–CD4+ cells is still an open question. It is clear that T cells with regulatory properties and an anergic pheno- type (such as the aforementioned Tr1 cells) can be generated in the periphery, but whether these are identical to naturally occurring TR cells remains to be established. Several approaches have led to the peripheral generation of regulatory cells. For instance, activation of conventional T cells in the presence of TGF-β/IL-10 or with the immunomodulatory agent 1-α-25-dihydroxyvitamin D3 produces a suppressive T cell [44,45]. Also of potential interest is the induction of regulatory cells by immature or ‘tolerogenic’ dendritic cells (DCs) [46,47]. Additionally, in some now classic studies, Qin and colleagues were able to generate regulatory cells by the administration of nondepleting anti-CD4 monoclonal antibodies in vivo to thymectomised mice (reviewed in [48]). A final confirmation of whether such peripherally generated regulatory cells are contiguous with naturally occurring TR cells or are simply another T cell activation state will have to await the assessment of Foxp3 expression. A summary of TR cell developmental steps is shown in Fig. 1. Mechanisms of suppression The suppression mechanism of activation-induced regulatory cells such as Tr1 cells is based primarily on the secretion of anti-inflammatory cytokines such as IL-10 and TGF-β (reviewed in [49]). The situation with naturally occurring TR cells is not nearly so clear-cut and despite intense interest remains strangely inconclusive. Potential TR cell suppression mechanisms can basically be divided into those mediated by secreted factors and those requiring intimate cell–cell contact. Most of the experiments in vivo examining TR cell suppression have been based on the murine IBD model described above and have, as with Tr1 cells, flagged the importance of IL-10 and TGF-β. By blocking IL-10 signalling in vivo with monoclonal antibodies against the IL-10 receptor, Asseman and colleagues were able to abrogate the normal IBD-preventative action of CD45RBlow T cells [50]. The same group was also able to show that CD45RBlow T cells from IL-10-deficient mice were unable to prevent colitis and, moreover, were even colitogenic themselves [50]. The importance of IL-10 in Available online http://arthritis-research.com/content/6/1/19 Figure 1 A putative scheme for the development of regulatory T (TR) cells. TR and naïve conventional helper T cells (Th0) develop within a normal thymus through the processes of positive and negative selection. Precursor T cells of relatively high avidity trigger a TR cell developmental programme involving the activation of Foxp3, whereas T cell receptors of intermediate avidity yield Th0 cells. Additionally, regulatory cells can be peripherally generated (for example, Tr1 cells) when activated under tolerogenic conditions (for example, with immature dendritic cells). As yet it is unclear whether de facto Foxp3+ TR cells can be generated in the periphery or whether the Tr1 cells produced from conventional Th0 cells are equivalent to naturally present TR cells. IL, interleukin; TE cell, effector T cell; TGF, transforming growth factor. the control of IBD is also implied by the observation that IL-10–/– mice spontaneously develop IBD even though these mice are not lymphopoenic [51]. Similarly, several groups have shown that a monoclonal-antibody-mediated blockade of TGF-β abrogates TR cell suppressive functions both in vivo and in vitro [52,53]. Interestingly, TGF-β does not necessarily have to act as a soluble factor but can be expressed exclusively on the surface of CD25+CD4+ cells after stimulation through the TCR and might therefore mediate its effects in a membraneproximal manner [53]. The level at which these anti-inflammatory cytokines operate to maintain tolerance is also uncertain, but it might be through the inhibition of APCs or pathogenic T cells, by maintenance of the TR cell population and/or by enhancement of their function (reviewed in [54]). Elucidation of the mechanism of TR cell suppression is complicated by the fact that most evidence in vitro shifts the emphasis of suppression to mechanisms solely based on cell contact. First, anti-IL-10 or anti-TGF-β monoclonal antibody fails to perturb the suppressive activity of CD25+CD4+ cells in vitro [54], although the use of soluble IL-10R seems to have a partial effect [55]. A study showing the successful neutralisation of suppression with antiTGF-β monoclonal antibodies at the same time also demonstrated the TGF-β to be bound to the cell surface [53]. Second, culture supernatants from activated CD25+CD4+ cells show no inherent suppressive ability, nor is any suppression observed across a semi-permeable membrane [37,38]. Taken together, the data in vitro thus seem to obviate the role of not merely IL-10/TGF-β but also soluble factors in general, suggesting that TR cell suppression is dependent on close cell–cell contact, although it is still impossible to discount completely the possibility that suppression is mediated in an extreme paracrine fashion. The membrane events that occur during cell contactdependent suppression are entirely unclear, but presum- Figure 2 Possible mechanisms of regulatory T (TR) cell suppression. These mechanisms are not necessarily mutually exclusive, and potentially two or more might act in concert. (a) Antigen-presenting cell (APC)-activated TR cells transduce an unidentified active negative signal to nearby effector T (TE) cells located on the same APC or an adjacent one. (b) TR cells outcompete TE cells for stimulatory ligands on the APC surface by virtue of their high expression of adhesion molecules. (c) TR cells modulate the behaviour of the APC so that they become ineffective or suppressive stimulators of TE cells. (d) CD25 expression by the TR cells acts as an interleukin-2 sink and hinders the autocrine/paracrine stimulation of TE cells. 23 Arthritis Research & Therapy Vol 6 No 1 Fehérvári and Sakaguchi ably an as yet uncharacterised inhibitory molecule is expressed on the surface of activated TR cells (see Fig. 2). Another mechanism of suppression mediated by cell contact could proceed via simple competition for APCs and specific major histocompatibility complex-peptide antigenic complexes. The high level of adhesion molecules and chemokine receptors present on the surface of TR cells would make them particularly well suited to homing to, and stably interacting with, APCs, thereby physically excluding normal CD25–CD4+ effector cells. Furthermore, constitutive expression of the high-affinity IL-2R would make TR cells into an effective sink for IL-2, depriving potential autoreactive cells of this essential growth factor. A final, conceptually attractive model of suppression would be TR cell-mediated inhibition or alteration of APC function. Supporting this model is the observation that CD25+CD4+ cells could alter the antigen-presenting function of DC by downregulating their expression levels of CD80/CD86 [56] or, as has recently been demonstrated, by triggering the immunosuppressive catabolism of tryptophan by DC [57]. Although APC perturbation might well occur in vivo, it is not essential because TR cells are able to suppress effectively even in the absence of any APCs [58]. Conclusion Solid evidence now strongly supports the existence of the once controversial TR cells as key controllers of selftolerance. Although limitations of space have forced this review to focus primarily on the role of TR cells and autoimmunity, there are ample data to suggest that this lineage might be crucial wherever immune reactions need to be regulated or tuned. For instance, TR cells might limit anti-tumour or microbial immune responses. A strategic manipulation of TR cells might thus be used either to enhance or to dampen immune responses as required. The identification of molecular markers, in particular Foxp3, has permitted the accurate isolation and study of these cells in ways not previously possible and will, it is hoped, facilitate therapeutic intervention with this potentially powerful immunological ally. Competing interests 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. None declared. Acknowledgements We thank our colleagues at Kyoto University for stimulating discussion and for permission to cite prepublication work. ZF is supported by a research fellowship from the Japan Society for the Promotion of Sciences. 19. 20. References 1. 2. 3. 24 Cohen IR: Regulation of autoimmune disease physiological and therapeutic. Immunol Rev 1986, 94:5-21. Arnold B: Levels of peripheral T cell tolerance. Transpl Immunol 2002, 10:109-114. Gershon RK, Kondo K: Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18: 723-737. 21. 22. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257. Nishizuka Y, Sakakura T: Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969, 166:753-755. Sakaguchi S, Sakaguchi N: Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J Immunol 1989, 142:471-480. Sakaguchi N, Miyai K, Sakaguchi S: Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J Immunol 1994, 152: 2586-2595. Seddon B, Mason D: Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4+CD45RC– cells and CD4+CD8– thymocytes. J Exp Med 1999, 189:279-288. Sakaguchi S, Takahashi T, Nishizuka Y: Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 1982, 156:1577-1586. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y: Prevention of postthymectomy autoimmune thyroiditis in mice. Lab Invest 1976, 34:601-605. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T: Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985, 161:7287. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993, 5:1461-1471. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic selftolerance. J Immunol 1999, 162:5317-5326. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S: Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000, 192:303-310. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG: B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001, 2:1126-1132. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D’Ambrosio D: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med 2001, 194: 847-853. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A: Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat Immunol 2002, 3:33-41. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142. Available online http://arthritis-research.com/content/6/1/19 23. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S: Naturally anergic and suppressive CD25+CD4+ T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000, 12:1145-1155. 24. Almeida AR, Legrand N, Papiernik M, Freitas AA: Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002, 169:4850-4860. 25. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4: 337-342. 26. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 27. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336. 28. Lyon MF, Peters J, Glenister PH, Ball S, Wright E: The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott–Aldrich syndrome. Proc Natl Acad Sci USA 1990, 87:2433-2437. 29. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB: Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci USA 1991, 88:5528-5532. 30. Blair PJ, Bultman SJ, Haas JC, Rouse BT, Wilkinson JE, Godfrey VL: CD4+CD8– T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J Immunol 1994, 153:37643774. 31. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3: 541-547. 32. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming β1 gene results in multifocal inflammatory growth factor-β disease. Nature 1992, 359:693-699. 33. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73. 34. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21. 35. Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39: 537-545. 36. Walker MR, Kasprowicz DJ, Gersuk VH, Bènard A, Van Landeghen M, Buckner JH, Ziegler SF Jr: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells. J Clin Invest 2003, 112:1437-1443. 37. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10:1969-1980. 38. Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296. 39. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM: Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247. 40. Suto A, Nakajima H, Ikeda K, Kubo S, Nakayama T, Taniguchi M, Saito Y, Iwamoto I: CD4+CD25+ T-cell development is regulated by at least 2 distinct mechanisms. Blood 2002, 99:555560. 41. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, Naji A, Caton AJ: Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001, 2:301-306. 42. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM: Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+25+ immunoregulatory T cells. J Exp Med 2001, 194:427-438. 43. Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W, Yoshida K, Sato T, Habu S, Itoh M, Sakaguchi N, Sakaguchi S, Kikutani H: Increased T cell autoreactivity in the absence of CD40–CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001, 166:353-360. 44. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L: Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001, 167:1945-1953. 45. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA: A role for TGFbeta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001, 166:7282-7289. 46. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192:12131222. 47. Sato K, Yamashita N, Baba M, Matsuyama T: Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003, 18:367-379. 48. Cobbold S, Waldmann H: Infectious tolerance. Curr Opin Immunol 1998, 10:518-524. 49. Groux H: Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003, 75:8S-12S. 50. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190: 995-1004. 51. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J Clin Invest 1996, 98:1010-1020. 52. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996, 183:2669-2674. 53. Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194:629-644. 54. Takahashi T, Sakaguchi S: The role of regulatory T cells in controlling immunologic self-tolerance. Int Rev Cytol 2003, 225:1-32. 55. Zhang X, Izikson L, Liu L, Weiner HL: Activation of CD25+CD4+ regulatory T cells by oral antigen administration. J Immunol 2001, 167:4245-4253. 56. Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000, 30:1538-1543. 57. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P: Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4:1206-1212. 58. Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137-1140. Correspondence Shimon Sakaguchi, Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Sakyo-ku, Kyoto 6068507, Japan. Tel: +81 75 751 3888; fax: +81 75 751 3820; e-mail: shimon@frontier.kyoto-u.ac.jp 25